MediWound

About

Funding history · 12 rounds · $370.5M total

Headcount over time

Q&A

What is MediWound's primary focus?

MediWound is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair.

What is NexoBrid® and where is it marketed?

NexoBrid® is MediWound's FDA-approved biologic indicated for the enzymatic removal of eschar in thermal burns. It is marketed in the U.S., European Union, Japan, and other international markets.

What is MediWound's current stage of development for EscharEx®?

EscharEx® is a late-stage investigational therapy for the debridement of chronic wounds.

When did MediWound become a public company?

MediWound became public on NASDAQ in March 2014, with an IPO of $75,000,000 at a valuation of $400,000,000.

What was MediWound's most recent funding round?

In July 2024, MediWound received a Grant of $2,500,000.

What was a significant recent development for NexoBrid®?

In August 2024, MediWound announced U.S. Food and Drug Administration approval of NexoBrid® for the treatment of pediatric patients with severe thermal burns.

What is the status of MediWound's manufacturing facility for NexoBrid®?

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid®.

What is MediWound's current employee count?

MediWound has 51-200 employees.

What is MediWound's market capitalization?

MediWound's market capitalization is $236,683,653.

Team · 2

Lior Rosenberg

Founder · Founder

Marian Gorecki

Founder · Co-founder

Sectors & technology

Highlights

Tags